Baupost Group - THERAVANCE BIOPHARMA INC ownership

THERAVANCE BIOPHARMA INC's ticker is and the CUSIP is 88339KAA0. A total of 22 filers reported holding THERAVANCE BIOPHARMA INC in Q1 2019. The put-call ratio across all filers is - and the average weighting 0.6%.

Quarter-by-quarter ownership
Baupost Group ownership history of THERAVANCE BIOPHARMA INC
ValueSharesWeighting
Q2 2022$25,912,000
-9.3%
28,104,000
-6.3%
0.38%
+24.8%
Q1 2022$28,562,000
-0.8%
30,000,0000.0%0.31%
+8.1%
Q4 2021$28,783,000
+4.1%
30,000,0000.0%0.28%
+11.8%
Q3 2021$27,640,000
-3.2%
30,000,0000.0%0.25%
+9.5%
Q2 2021$28,559,000
-6.6%
30,000,0000.0%0.23%
-4.9%
Q1 2021$30,580,000
+7.7%
30,000,0000.0%0.24%
-6.9%
Q4 2020$28,396,000
+8.0%
30,000,0000.0%0.26%
-7.7%
Q3 2020$26,281,000
-9.9%
30,000,0000.0%0.28%
-22.0%
Q2 2020$29,184,000
+1.7%
30,000,0000.0%0.36%
-13.9%
Q1 2020$28,688,000
-7.8%
30,000,0000.0%0.42%
+23.0%
Q4 2019$31,118,000
+12.5%
30,000,0000.0%0.34%
+9.9%
Q3 2019$27,656,000
+7.5%
30,000,0000.0%0.31%
+34.3%
Q2 2019$25,725,000
-11.9%
30,000,0000.0%0.23%
-4.9%
Q1 2019$29,213,000
-5.3%
30,000,0000.0%0.24%
-8.6%
Q4 2018$30,863,000
-10.7%
30,000,0000.0%0.27%
+1.1%
Q3 2018$34,575,000
+15.4%
30,000,0000.0%0.26%
+1.1%
Q2 2018$29,963,000
-0.8%
30,000,0000.0%0.26%
-10.0%
Q1 2018$30,206,000
-8.6%
30,000,0000.0%0.29%
-11.0%
Q4 2017$33,038,000
-11.0%
30,000,0000.0%0.33%
-29.4%
Q3 2017$37,125,000
-8.1%
30,000,0000.0%0.46%
+0.4%
Q2 2017$40,388,000
+7.0%
30,000,0000.0%0.46%
+3.6%
Q1 2017$37,763,000
+10.9%
30,000,0000.0%0.44%
+0.2%
Q4 2016$34,059,00030,000,0000.44%
Other shareholders

There were no reported owners of THERAVANCE BIOPHARMA INC in Q1 2019.

NameSharesValueWeighting ↓
View complete list of THERAVANCE BIOPHARMA INC shareholders